A Phase 3 interventional study of Bimekizumab in Chronic Plaque Psoriasis and Moderate to Severe Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 39 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-14.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.
Among the 20 studies testing bimekizumab in Psoriasis, this one is the 10th largest by enrollment, is one of 4 that started in 2018, is one of 10 in phase 3, and was the 10th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Canada, China and 10 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–45
University Hospital, Rouen · Sites in France
Ages 18–60
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 172 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 161 across the 20 interventional studies. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 8 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
26 studies in Psoriasis by UCB S.A.: 1 open now, 2 under way, 2 of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 26 studies in Psoriasis by UCB S.A., this one is the 14th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2018, is one of 14 in phase 3, and was the 18th registered.
UCB S.A.’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing bimekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 26 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the ability of subjects with moderate to severe chronic plaque psoriasis (PSO) to safely and effectively self-inject bimekizumab at study start and 8 weeks after training in self-injection technique using a prefilled safety syringe or an auto-injector.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive assigned bimekizumab dose regimen using a prefilled safety syringe (SS).
Drug: Bimekizumab
Subjects will receive assigned bimekizumab dose regimen using an auto-injector (AI).
Drug: Bimekizumab
Subjects will receive bimekizumab at pre-specified time-points.
Also known as: UCB4940, BKZ
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-safety Syringe (SS)-1mL or the Bimekizumab-auto-injector (AI)-1mL at Week 8, After Training in Self-injection Technique
Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-safety syringe (SS) or the bimekizumab-auto-injector (AI) which shows that the investigational medicinal product (IMP) was delivered completely (ie, container is empty), and - No Adverse Device Effects (ADEs) that would preclude continued use of the device for self-injection (ie, no serious ADEs (SADEs) and/or ADEs leading to withdrawal).
Time frame: Week 8
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Week 8, After Training in Self-injection Technique
Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which shows that the IMP is delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no serious ADEs (SADEs) and/or ADEs leading to withdrawal).
Time frame: Week 8
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-1mL or the Bimekizumab-AI-1mL at Baseline, After Training in Self-injection Technique
Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which showed that the IMP was delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no SADEs and/or ADEs leading to withdrawal).
Time frame: Baseline (the first self-injection visit)
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Baseline, After Training in Self-injection Technique
Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which shows that the IMP is delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no SADEs and/or ADEs leading to withdrawal).
Time frame: Baseline (the first self-injection visit)
The study started to enroll study participants in December 2018 and concluded in September 2020. This study is a substudy to PS0014 (NCT03598790).
| Milestone | Bimekizumab-SS-1mL 320 mg | Bimekizumab-AI-1mL 320 mg | Bimekizumab-SS-2mL 320 mg | Bimekizumab-AI-2mL 320 mg |
|---|---|---|---|---|
| Started | 66 | 68 | 19 | 19 |
| Completed | 65 | 61 | 19 | 18 |
| Not completed | 1 | 7 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event, not fatal | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 2 | 0 | 0 |
Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-safety syringe (SS) or the bimekizumab-auto-injector (AI) which shows that the investigational medicinal product (IMP) was delivered completely (ie, container is empty), and - No Adverse Device Effects (ADEs) that would preclude continued use of the device for self-injection (ie, no serious ADEs (SADEs) and/or ADEs leading to withdrawal).
| percentage of participants | Bimekizumab-SS-1mL 320 mg (FAS-s-1mL) | Bimekizumab -AI-1mL 320 mg (FAS-a-1mL) |
|---|---|---|
| Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-safety Syringe (SS)-1mL or the Bimekizumab-auto-injector (AI)-1mL at Week 8, After Training in Self-injection Technique | 100 (95.4 to 100) | 100 (95.3 to 100) |
Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which shows that the IMP is delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no serious ADEs (SADEs) and/or ADEs leading to withdrawal).
| percentage of participants | Bimekizumab-SS-2mL 320 mg (FAS-s-2mL) | Bimekizumab-AI-2mL 320 mg (FAS-a-2mL) |
|---|---|---|
| Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Week 8, After Training in Self-injection Technique | 100 (85.4 to 100) | 94.7 (77.4 to 99.7) |
Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which showed that the IMP was delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no SADEs and/or ADEs leading to withdrawal).
| percentage of participants | Bimekizumab-SS-1mL 320 mg (FAS-s-1mL) | Bimekizumab -AI-1mL 320 mg (FAS-a-1mL) |
|---|---|---|
| Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-1mL or the Bimekizumab-AI-1mL at Baseline, After Training in Self-injection Technique | 100 (95.4 to 100) | 97.1 (91.0 to 99.5) |
Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which shows that the IMP is delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no SADEs and/or ADEs leading to withdrawal).
| percentage of participants | Bimekizumab-SS-2mL 320 mg (FAS-s-2mL) | Bimekizumab-AI-2mL 320 mg (FAS-a-2mL) |
|---|---|---|
| Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-SS-2mL or the Bimekizumab-AI-2mL at Baseline, After Training in Self-injection Technique | 100 (85.4 to 100) | 100 (85.4 to 100) |
Collected over From Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bimekizumab-SS-1mL 320 mg (SS-s-1mL) | 0/65 (0%) | 0/65 (0%) | 0/65 (0%) |
| Bimekizumab AI-1mL 320 mg (SS-a-1mL) | 0/68 (0%) | 0/68 (0%) | 0/68 (0%) |
| Bimekizumab-SS-2mL 320 mg (SS-s-2mL) | 0/19 (0%) | 0/19 (0%) | 1/19 (5.3%) |
| Bimekizumab-AI-2mL 320 mg (SS-a-2mL) | 0/19 (0%) | 0/19 (0%) | 1/19 (5.3%) |
| Event | Bimekizumab-SS-1mL 320 mg (SS-s-1mL) | Bimekizumab AI-1mL 320 mg (SS-a-1mL) | Bimekizumab-SS-2mL 320 mg (SS-s-2mL) | Bimekizumab-AI-2mL 320 mg (SS-a-2mL) |
|---|---|---|---|---|
| Injection site reactionGeneral disorders | 0/65 | 0/68 | 1/19 | 0/19 |
| Injection site painGeneral disorders | 0/65 | 0/68 | 0/19 | 1/19 |
Baseline Characteristics refer to the Safety Set (SS) consisted of all study participants who received at least 1 dose of bimekizumab by the indicated self-injection investigational device presentation (bimekizumab-SS-1mL SS \[SS-s\], bimekizumab-AI-1mL SS \[SS-a\], bimekizumab-SS-2mL SS \[SS-s\] and bimekizumab-AI-2mL SS \[SS-a\]). One study participant included in the Enrolled Set did not self-inject at any time during the study and is therefore not included in the Safety Set (SS-s-1mL).
| Age, Categorical(Participants) | Bimekizumab-SS-1mL 320 mg (SS-s-1mL) | Bimekizumab AI-1mL 320 mg (SS-a-1mL) | Bimekizumab-SS-2mL 320 mg (SS-s-2mL) | Bimekizumab-AI-2mL 320 mg (SS-a-2mL) | Total Title |
|---|---|---|---|---|---|
| <=18 years | 1 | 1 | 0 | 0 | 2 |
| Between 18 and 65 years | 57 | 59 | 16 | 18 | 150 |
| >=65 years | 7 | 8 | 3 | 1 | 19 |
| Age, Continuous(years) | Bimekizumab-SS-1mL 320 mg (SS-s-1mL) | Bimekizumab AI-1mL 320 mg (SS-a-1mL) | Bimekizumab-SS-2mL 320 mg (SS-s-2mL) | Bimekizumab-AI-2mL 320 mg (SS-a-2mL) | Total Title |
|---|---|---|---|---|---|
| Mean | 49.7 ± 13.4 | 46.8 ± 14.0 | 50.3 ± 15.8 | 43.0 ± 12.4 | 47.9 ± 13.9 |
| Sex: Female, Male(Participants) | Bimekizumab-SS-1mL 320 mg (SS-s-1mL) | Bimekizumab AI-1mL 320 mg (SS-a-1mL) | Bimekizumab-SS-2mL 320 mg (SS-s-2mL) | Bimekizumab-AI-2mL 320 mg (SS-a-2mL) | Total Title |
|---|---|---|---|---|---|
| Female | 22 | 19 | 9 | 9 | 59 |
| Male | 43 | 49 | 10 | 10 | 112 |
| Race/Ethnicity, Customized(Participants) | Bimekizumab-SS-1mL 320 mg (SS-s-1mL) | Bimekizumab AI-1mL 320 mg (SS-a-1mL) | Bimekizumab-SS-2mL 320 mg (SS-s-2mL) | Bimekizumab-AI-2mL 320 mg (SS-a-2mL) | Total Title |
|---|---|---|---|---|---|
| Asian | 2 | 2 | 1 | 2 | 7 |
| Black or African American | 2 | 2 | 1 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 | 0 | 2 |
| White | 60 | 61 | 16 | 16 | 153 |
| Other or Mixed | 1 | 2 | 0 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in Jul 2020, 18 months.
Results were first posted in Aug 2023, 3 years after primary completion. A results delay was requested in Jun 2021.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab